Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Adverse Event Reporting Systems To Be Integrated By Kevric

Executive Summary

FDA's adverse event reporting systems and CDC's infectious disease tracking system will be given a common website for physicians to submit data through a contract with The Kevric Company

You may also be interested in...



Adverse Event Voluntary Reporting Useful, Needs Standardization, IoM Says

Adverse event reporting can remain voluntary but should become more standardized, the Institute of Medicine suggests in a report on patient safety issues

Adverse Event Voluntary Reporting Useful, Needs Standardization, IoM Says

Adverse event reporting can remain voluntary but should become more standardized, the Institute of Medicine suggests in a report on patient safety issues

Merck Builds Risk Management Into Drug Development; Hires FDA’s Honi

Merck is building risk management into its product development strategy with the hiring of FDA Office of Drug Safety Director Peter Honig, MD

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel